Diagnostic Tools of Waldenström's Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801QV2" target="_blank" >RIV/61988987:17110/17:A1801QV2 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.14735/amko20172S81" target="_blank" >http://dx.doi.org/10.14735/amko20172S81</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14735/amko20172S81" target="_blank" >10.14735/amko20172S81</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Diagnostic Tools of Waldenström's Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring

Popis výsledku v původním jazyce

Waldenströms macroglobulinemia (WM) is a B-cell malignancy characterized by high levelof monoclonal immunoglobulin M (IgM) paraprotein in blood serum and associated with thebone marrow infi ltration by malignant cells with lymphoplasmacytic diff erentiation. WM remainsincurable advances in therapy. Most of WM cases are associated with a somatic pointmutation L265P in MYD88. Signifi cantly higher risk of progression from the IgM monoclonalgammopathy of undetermined signifi cance (IgM MGUS) to WM for patients with mutatedMYD88 gene suggests that this mutation is an early oncogenic event and plays a central role indevelopment of malignant clones. The second, most prevalent mutation in WM is found in theCXCR4 gene and is often associated with drug resistance and aggressive disease presentation.Therefore, detection of these mutations (MYD88L265P and CXCR4S338X) could be useful dia gnosticand prognostic tool for the patients with WM. While detection of these mutations in bonemarrow sample is common, the aim of our study was to compare sensitivity of detection ofmutation from diff erent cell fraction from peripheral blood and bone marrow. The results showpossibility to describe MYD88 and CXCR4 mutation status even from peripheral blood sample(sensitivity for MYD88L265P was 100%, for CXCR4S338X 91%), which signifi cantly facilitate materialcollection. Moreover, comparable detection sensitivity of these mutations in bone marrow andperipheral blood samples examined before and during the therapy off ers a promising tool formore routine dia gnostic and monitoring of disease progression.

Název v anglickém jazyce

Diagnostic Tools of Waldenström's Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring

Popis výsledku anglicky

Waldenströms macroglobulinemia (WM) is a B-cell malignancy characterized by high levelof monoclonal immunoglobulin M (IgM) paraprotein in blood serum and associated with thebone marrow infi ltration by malignant cells with lymphoplasmacytic diff erentiation. WM remainsincurable advances in therapy. Most of WM cases are associated with a somatic pointmutation L265P in MYD88. Signifi cantly higher risk of progression from the IgM monoclonalgammopathy of undetermined signifi cance (IgM MGUS) to WM for patients with mutatedMYD88 gene suggests that this mutation is an early oncogenic event and plays a central role indevelopment of malignant clones. The second, most prevalent mutation in WM is found in theCXCR4 gene and is often associated with drug resistance and aggressive disease presentation.Therefore, detection of these mutations (MYD88L265P and CXCR4S338X) could be useful dia gnosticand prognostic tool for the patients with WM. While detection of these mutations in bonemarrow sample is common, the aim of our study was to compare sensitivity of detection ofmutation from diff erent cell fraction from peripheral blood and bone marrow. The results showpossibility to describe MYD88 and CXCR4 mutation status even from peripheral blood sample(sensitivity for MYD88L265P was 100%, for CXCR4S338X 91%), which signifi cantly facilitate materialcollection. Moreover, comparable detection sensitivity of these mutations in bone marrow andperipheral blood samples examined before and during the therapy off ers a promising tool formore routine dia gnostic and monitoring of disease progression.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Klinická onkologie

ISSN

1802-5307

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

11

Strana od-do

81-91

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85029470000